Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN6302 | L-Rhamnose |
| L-Rhamnose may exhibit excellent sodium-glucose transporter (SGLT1 and SGLT2) inhibition activity. L-fucose and especially L-rhamnose have anticancer potential, they exert a significant suppressive effect on tumour growth. | |
| BCN6312 | Naringin |
| Naringin exhibits antioxidant, anti-atherogenic, antiulcer, anti-hypocholesterolemic, anti-lipoperoxidative, and anti-hyperglycemia effects. Naringin reduces Ara-C-induced oxidative stress through both an inhibition of the generation of ROS production and an increase in antioxidant enzyme activities, it blocks apoptosis caused by Ara-C-induced oxidative stress, resulting in the inhibition of the cytotoxicity of Ara-C. Naringin attenuates epidermal growth factor (EGF)-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IκB-NF-κB signaling pathways. | |
| BCN6315 | Procyanidin B2 |
| Procyanidin B2 has vascular protective, anti-diabetic nephropathy, anti-cancer, anti-inflammatory, and antioxidant activities. Procyanidin B2 inhibited NLRP3 inflammasome activation via suppression of AP-1 pathway, and up-regulated the expression of GSTP1 via a mechanism that involves ERK and p38 MAPK activation and Nrf2 translocation. It has anti- and pro-oxidant effects on metal-mediated DNA damage by interacting with H2O2 and metal ions. | |
| BCN6317 | Procyanidin C1 |
| Procyanidin C1 has anti-inflammatory effects, can inhibit IKKb activity in vitro and reduce the LPS-induced production of ROS, thus, it exerts the anti-inflammatory effects by inhibiting ERK1/2 and IKKb activity. Procyanidin C1 could be useful as a lead compound to develop inhibitors of cancer metastasis and other diseases related to epithelial-to-mesenchymal transition (EMT). Procyanidin C1 may represent a novel and potentially therapeutically relevant compound for the treatment of cardiovascular diseases, it -induced vasorelaxation is associated with the activation of the calcium-dependent NO/cGMP pathway, involving potassium channel activation. | |
| BCN6318 | Sinomenine HCl |
| Sinomenine HCl is a blocker of the NF-κB activation and also an activator of μ-opioid receptor, which has antiarrhythmic, anti-inflammatory, anti-tumor, and neuroprotective effects. Sinomenine HCl can improve survival, reduce organ damage, and attenuate the release of inflammatory cytokines induced by CLP, at least in part through regulating autophagy activities, it induces breast cancer cell death through ROS-dependent and -independent pathways with an upregulation of MAPKs. | |
